In recent years, the central precocious puberty (CPP) treatment market is anticipated to grow rapidly during the forecast period. Gonadotropin-releasing hormone (GnRH) agonists may be used to treat CPP because they block the stimulating effects of endogenous GnRH and speed up bone development, preventing early puberty. Menarche is delayed when GnRH treatment is used to delay the onset of puberty. Triptodor, Lupron Depot-Ped (leuprolide acetate), and Supprelin LA (histrelin acetate) are three approved therapy drugs for central precocious puberty currently on the market (CPP).
